|allbiomedical > News & Topics >Bristol-Myers and Innate Pharma to Develop Cancer Drug
Bristol-Myers and Innate Pharma to Develop Cancer Drug
Author: Drug Discovery & Development Staff
Source From: Drug Discovery & Development
Posted Date: 2011-07-13
Bristol-Myers Squibb Company and Innate Pharma S.A. announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.
Under the terms of the agreement, Innate Pharma will grant to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture, and commercialize IPH2102 and related compounds blocking KIR receptors.
The agreement covers all potential indications for IPH2102. Innate Pharma will continue to develop IPH2102 in acute myeloid leukemia (AML) through the end of Phase II. Innate Pharma will also provide preclinical support for the development of IPH2102.
Bristol-Myers Squibb will fund the development of IPH2102, make an upfront payment of $35 million and additional payments of up to $430 million, depending on the achievement of pre-specified milestones during the development and commercialization period, as well as pre-specified tiered double-digit royalty payments on worldwide net sales.
Original Hyperlink: http://www.dddmag.com/Bristol-Myers-and-Innate-Pharma-to-Develop-Cancer-Drug-071..
For more information from this magazine/website? Please click here http://www.dddmag.com
About Us:Drug Discovery & Development magazine delivers insight into the full landscape of technologies, tools, and business/regulatory strategies that help scientists and executives accelerate the pace and productivity of drug research and development. Articles are concise, with practical intent: to present information for day-to-day technical and business decision-making.
Note: The copyright and the ownship of the brand, product names, product numbers, and content mentioned belongs to their repective companies.